KMB vs TARS · P/E 19, rev $8.35B vs rev $336.0M
Kimberly-Clark Corporation (KMB) versus Tarsus Pharmaceuticals Inc (TARS) — a side-by-side from cached financials, not a winner call.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
Latest reported KMB revenue for 2026-06-30 was $8.35B. Net income was $1.01B. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Latest reported TARS revenue for 2026-06-30 was $336.0M. Net income was -$25.5M. TARS currently screens at market cap $2.66B.
KMB currently screens at market cap $32.88B and trailing P/E 19.2. TARS currently screens at market cap $2.66B.
Not investment advice. Open the KMB and TARS stock pages for the full models.
Not investment advice.